• Personal or family history of Medullary Thyroid Cancer or in patients with multiple endocrine neoplasia syndrome type 2

• Known hypersensitivity to GLP-1 or to any of the product components

• If you are pregnant or plan to become pregnant within the next 2 months or are currently breastfeeding, we do not offer GLP-1 therapy per our established protocols

BMI less than 27 will disqualify you from receiving GLP-1 therapy from Hydrations Wellness per our established protocols.

Clients new to GLP-1 injections will need to complete some intake forms prior to beginning their first injection.  A Medical review will be completed within 1-2 business days and you will be notified of your eligibility.  You may also complete these forms online if you prefer by CLICKING HERE

Upon Approval, you will be required to pay $125/month at the beginning of week 1, week 5, week 9 and week 13 injections.  If you discontinue use, no refunds will be able to be given for the month in which you prepaid after the first injection for that month has been given.

MAINTENANCE/EXISTING USERS

Once you complete your 4 month protocol, you will be able to pay for your maintenance dose injections at time of service.  If you are an existing user who started GLP-1 therapy prior to visiting Hydrations Wellness, you will need to provide a copy of your prescription for verification before receiving your first injection with us.

SELF-CARE USERS

Clients who have completed at least 4 maintenance does injections may opt to purchase the vial/supplies in order to perform their own injections at home.  You will still need to come and pickup your vial/supplies at Hydrations Wellness and prepay prior to having them ordered.  No refunds on payment for vial/supplies once the prescription has been submitted to the pharmacy by Hydrations Wellness.

• Based on findings in rats and mice, GLP-1 therpay may cause thyroid C-cell tumors, including MTC, in humans as human relevance of Semaglutide-induced rodent thyroid C-cell tumors has not been determined
• In control trials, acute pancreatitis was reported (0.3 events [SC] per 100 patient years);  After initiating treatment, monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting);  If pancreatitis is suspected, discontinue GLP-1 Therapy and do not restart if confirmed
• Patients treated with GLP-1 Therapy showed an increased risk of diabetic retinopathy complications compared with placebo/comparator; rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy
• Post-marketing reports describe acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis in patients treated with GLP-1 receptor agonists; a majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration; We may require bloodwork to monitor renal function when initiating or escalating doses of GLP-1 Therapy in patients reporting adverse GI reactions




• Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists; if hypersensitivity reactions occur, discontinue treatment, treat promptly, and monitor until signs and symptoms resolve

• nausea,
• vomiting,
• stomach pain,
• loss of appetite,
• diarrhea, and/or constipation

If you experience these side effects, we will lower your dosage to the last dose tolerated without side effects.

Serious/Rare side effects of Semaglutide include:

• hives,
• itching,
• dizziness,
• fast heartbeats,
• difficult breathing,
• swelling of the face, lips, tongue, or throat,
• vision changes,
• swelling or a lump in the neck,
• trouble swallowing,
• hoarse voice,
• shortness of breath,
• severe pain in your upper stomach spreading to the back,
• nausea with or without vomiting,
• headache,
• hunger,
• weakness,
• sweating,
• confusion,
• irritability,
• dizziness,
• feeling jittery,
• little or no urination,
• swelling in the feet or ankles, and
• tiredness

If you experience these side effects, seek immediate medical attention.  You will no longer be eligible for future injections.

Gliclazide, glipizide, glibenclamide, glimepiride, nateglinide and repaglinide.

These drugs are more likely to cause hypoglycemic events in diabetics who use GLP-1 for weight loss.

Precautions should be taken when using non-prescription medications as well.  Per Mayo Clininc, the medications include:

OTC medicines for: appetite control, asthma, colds, cough, hay fever, or sinus problems.